Maxwell Skor
Stock Analyst at Morgan Stanley
(4.39)
# 1,174
Out of 4,408 analysts
206
Total ratings
61.5%
Success rate
15.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintained: Buy | $41 | $31.54 | +29.99% | 84 | Jun 15, 2026 | |
| CRSP CRISPR Therapeutics AG | Upgraded: Hold | $60 | $52.61 | +14.05% | 1 | Jun 11, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $103 | $71.38 | +44.30% | 19 | May 18, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $256 | $223.29 | +14.65% | 22 | May 18, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Hold | $12 | $4.15 | +189.16% | 8 | May 18, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $115 | $61.47 | +87.08% | 2 | May 18, 2026 | |
| AVIR Atea Pharmaceuticals | Maintained: Hold | $6 | $4.35 | +37.93% | 9 | May 18, 2026 | |
| SANA Sana Biotechnology | Maintained: Buy | $12 | $2.85 | +321.05% | 3 | May 18, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $67 | $25.38 | +163.99% | 11 | May 6, 2026 | |
| INSM Insmed | Maintained: Buy | $212 | $97.46 | +117.53% | 19 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.9504 | - | 5 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $77 → $87 | $35.07 | +148.09% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.64 | - | 6 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.8686 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.7004 | n/a | 1 | Sep 25, 2023 |
Pharvaris
Jun 15, 2026
Maintained: Buy
Price Target: $41
Current: $31.54
Upside: +29.99%
CRISPR Therapeutics AG
Jun 11, 2026
Upgraded: Hold
Price Target: $60
Current: $52.61
Upside: +14.05%
Cytokinetics
May 18, 2026
Maintained: Buy
Price Target: $103
Current: $71.38
Upside: +44.30%
Ascendis Pharma
May 18, 2026
Maintained: Buy
Price Target: $256
Current: $223.29
Upside: +14.65%
Bicycle Therapeutics
May 18, 2026
Maintained: Hold
Price Target: $12
Current: $4.15
Upside: +189.16%
Monopar Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $115
Current: $61.47
Upside: +87.08%
Atea Pharmaceuticals
May 18, 2026
Maintained: Hold
Price Target: $6
Current: $4.35
Upside: +37.93%
Sana Biotechnology
May 18, 2026
Maintained: Buy
Price Target: $12
Current: $2.85
Upside: +321.05%
Ultragenyx Pharmaceutical
May 6, 2026
Maintained: Buy
Price Target: $67
Current: $25.38
Upside: +163.99%
Insmed
Apr 7, 2026
Maintained: Buy
Price Target: $212
Current: $97.46
Upside: +117.53%
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $0.9504
Upside: -
Jan 8, 2026
Maintained: Buy
Price Target: $77 → $87
Current: $35.07
Upside: +148.09%
Aug 22, 2025
Maintained: Hold
Price Target: n/a
Current: $3.64
Upside: -
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.8686
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.7004
Upside: n/a